53727-29-0

Basic information

• Product Name: 1-METHYL-3-PHENYL-PYRIMIDINE-2,4,6-TRIONE
• Synonyms: 1-METHYL-3-PHENYL-PYRIMIDINE-2,4,6-TRIONE;1-Methyl-3-phenylbarbituric acid
• CAS NO: 53727-29-0
• Molecular Formula: C₁₁H₁₀N₂O₃
• Molecular Weight: 218.2087
• Mol File: 53727-29-0.mol
• Article Data: 2

Chemical Properties

• Melting Point: 118-122 °C
• Boiling Point: 333.4±25.0 °C(Predicted)
• Appearance: /
• Density: 1.344±0.06 g/cm3(Predicted)
• PKA: 5.79±0.40(Predicted)
• CAS DataBase Reference: 1-METHYL-3-PHENYL-PYRIMIDINE-2,4,6-TRIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-3-PHENYL-PYRIMIDINE-2,4,6-TRIONE(53727-29-0)
• EPA Substance Registry System: 1-METHYL-3-PHENYL-PYRIMIDINE-2,4,6-TRIONE(53727-29-0)

Safety Data

• Hazardous Substances Data: 53727-29-0(Hazardous Substances Data)

Usage

General Description

1-METHYL-3-PHENYL-PYRIMIDINE-2,4,6-TRIONE, also known as Methylphenidate or Ritalin, is a central nervous system stimulant. It is commonly used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Methylphenidate works by increasing the levels of dopamine and norepinephrine in the brain, leading to improved focus, attention, and impulse control. It is available in various forms, including immediate-release and extended-release tablets, and is generally well-tolerated, although it may cause side effects such as insomnia, loss of appetite, and increased heart rate. Methylphenidate is classified as a Schedule II controlled substance in the United States, indicating a high potential for abuse and dependence.

Upstream product

• 21236-97-5 3-methyl-6-aminouracil 
• 141-82-2 malonic acid 
• 1007-36-9 1-methyl-3-phenylurea 
• 72702-74-0 N-cyanoacetyl-N-methyl-N'-phenyl-urea 
• 42212-19-1 6-amino-3-methyl-1-phenylpyrimidine-2,4(1H,3H)dione 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 53680-90-3 6-chloro-3-methyl-1-phenylpyrimidine-2,4(1H,3H)-dione 
• 176378-93-1 acetic acid 3-acetoxy-5-(3-methyl-6-methylamino-2,4-dioxo-1-phenyl-1,2,3,4-tetrahydro-pyrimidin-5-ylcarbamoyl)-phenyl ester 
• 176379-59-2 5-amino-3-methyl-6-methylamino-1-phenyluracil 
• 146723-69-5 3-methyl-6-methylamino-1-phenyluracil 
• 53681-13-3 6-hydrazino-3-methyl-1-phenyl-1H-pyrimidine-2,4-dione 
• 92978-75-1 5-(N,N-dimethylaminomethylene)-1-methyl-3-phenylbarbituric acid 
• 99851-82-8 5-bromo-1-methyl-3-phenyl-barbituric acid 

Relevant articles and documents

Synthesis and biological evaluation of CX-659S and its related compounds for their inhibitory effects on the delayed-type hypersensitivity reaction

In order to find novel nonsteroidal compounds possessing an inhibitory activity against delayed-type hypersensitivity (DTH) reactions, we conducted random screening using a picryl chloride (PC)-induced contact hypersensitivity reaction (CHR) in mice, and found compound 1 as a lead compound. Then we synthesized and evaluated an extensive series of 5-carboxamidouracil derivatives focused on both the uracil and the antioxidative moieties. Among them, we found that the hindered phenol moiety was necessary to exhibit the activities; especially, compounds 28a-28c having the partial structure of vitamin E were found to exert potent activities against the DTH reaction by both oral and topical administration. And compound 28c showed antioxidative activity against lipid peroxidation with an IC50 of 5.9μM. Compound 28c (CX-659S) was chosen as a candidate drug for the treatment of cutaneous disorders such as atopic dermatitis and allergic contact dermatitis. Copyright (C) 2000 Elsevier Science Ltd.